Investigators from the Icahn Medical School in Mount Sinai (New York, EEUU) identified three major molecular subtypes of Alzheimer’s disease using ARN sequencing data, which is a genetic molecule similar to DNA that encodes the instructions for producing proteins.
The work is advancing in our understanding of the mechanisms of Alzheimer’s disease and the ability to wrap the truck around it development of new and personalized therapies is treated by the most common form of dementia, but is quite diverse in its biological and pathological manifestations.
In the news, there is a clear evidence that progression of illness and responses to interventions differ significantly between Alzheimer’s patients. Some patients have a cognitive deterrent, while others are the fastest deterrent; some have a significant memory loss and an inability to record new information, while others do not; and some patients experiencing psychosis and / or depression associated with illness, while others no.
“Different languages suggest strongly that hay subtypes Alzheimer’s disease with various biological and molecular factors that stimulate the progression of the disease “, said bin Zhang, author of the study.
The work, published in Science Advances, contains more than 1,500 ARN sequencing dates in five regions of the cerebral cerebral palsy, and routines for routine checks, and identified three major molecular subtypes of Alzheimer’s disease. These subtypes are independently identified by the age and stage of the nurse, and are replicated in multiple regions of the brain in cohort studies.
Objective: precision medicine for Alzheimer’s
These are subtypes correspond to different combinations of multiple biological pathways that regulate cerebral degeneration. The neurofibrillary nerve Tau and the beta-amyloid plaque, the neuropathological characteristics of Alzheimer’s, significantly increase only in subtypes.
“Our identification and systematic characterization of the robust molecular subtypes of the Alzheimer’s Revelation reveals many ways in which new regulation is regulated in the field of disease and new objective signaling. These are based on the basics for determining the most effective biomarkers for Alzheimer’s temperament prediction, studying causal mechanisms, developing proximal generation therapies, and designing more effective and specific clinical trials.. Future challenges in terms of investigation include the replication of the halls in larger cohorts, the validation of specific objectives and mechanisms of subtypes, the identification of peripheral biomarkers and the most common characteristics.